|
|
|
Volumn 2, Issue 1, 2000, Pages 25-39
|
|
Developing novel antipsychotic drugs: Strategies and goals
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE;
3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE;
ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL;
ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE;
ARIPIPRAZOLE;
CHLORPROMAZINE;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
CLOZAPINE;
CYCLOSERINE;
DIZOCILPINE;
DOPAMINE 2 RECEPTOR;
GLYCINE;
HALOPERIDOL;
MUSCARINIC AGENT;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
NEUROLEPTIC AGENT;
OLANZAPINE;
QUETIAPINE;
REMOXIPRIDE;
RISPERIDONE;
SEROTONIN 1A AGONIST;
SERTINDOLE;
THIORIDAZINE;
ZIPRASIDONE;
AGRANULOCYTOSIS;
AMNESIA;
APLASTIC ANEMIA;
CLINICAL TRIAL;
COGNITIVE DEFECT;
DELIRIUM;
DISEASE MODEL;
DOSE RESPONSE;
DRUG BINDING;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG STRUCTURE;
EXTRAPYRAMIDAL SYMPTOM;
GASTROINTESTINAL SYMPTOM;
HEART ARRHYTHMIA;
HUMAN;
NONHUMAN;
REVIEW;
SCHIZOPHRENIA;
TARDIVE DYSKINESIA;
WEIGHT GAIN;
|
|
EID: 0034091854
PISSN: 1464844X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (29)
|
|
References (152)
|
